Stock Analysis
Simcere Pharmaceutical Group First Half 2024 Earnings: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)
Simcere Pharmaceutical Group (HKG:2096) First Half 2024 Results
Key Financial Results
- Revenue: CN¥3.11b (down 7.9% from 1H 2023).
- Net income: CN¥456.6m (down 80% from 1H 2023).
- Profit margin: 15% (down from 67% in 1H 2023).
- EPS: CN¥0.18 (down from CN¥0.87 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Simcere Pharmaceutical Group Earnings Insights
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are down 4.7% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Simcere Pharmaceutical Group's balance sheet.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2096
Simcere Pharmaceutical Group
Engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China.